Scinus Group closes €3 million to expand cell therapy automation
Utrecht-based Scinus Group has raised €3 million to scale its automated cell therapy manufacturing platform, aiming to make advanced therapies more reliable, affordable and accessible across Europe. The fresh capital will be used to industrialize the company’s technology, expand production capacity and deepen partnerships with hospitals and biopharmaceutical companies.
Automating complex cell therapy workflows
Scinus Group develops an integrated platform that automates key steps in the production of cell-based therapies, from cell expansion to quality control. By replacing manual, labor‑intensive procedures with closed, software‑driven systems, the company seeks to reduce variability, lower costs and shorten time‑to‑treatment for patients.
The platform is designed to support a wide range of advanced modalities, including CAR‑T therapies, stem cell treatments and other personalized medicines that require highly controlled processing environments. Automation and robust bioprocessing are increasingly seen as critical to moving these therapies from small clinical programs to broader commercial use.
Strengthening Europe’s advanced therapy ecosystem
The €3 million funding round underscores growing investor confidence in European HealthTech and BioTech infrastructure. As regulators and healthcare systems push for scalable manufacturing of advanced therapy medicinal products (ATMPs), technology providers like Scinus Group are becoming central to the continent’s innovation pipeline.
With its base in Utrecht, a fast‑growing Dutch life sciences hub, Scinus Group plans to work closely with clinical centers and industry partners to validate its platform in real‑world settings. The company’s goal is to help standardize complex workflows, enabling more hospitals and manufacturers to deliver next‑generation therapies safely and at scale.
Positioning for future growth
The new capital will support hiring in bioprocess engineering, software development and regulatory operations, while funding further development of data‑driven automation and quality assurance tools. As demand for cell and gene therapies accelerates, Scinus Group is positioning itself as a key enabler of industrial‑grade manufacturing in Europe’s rapidly evolving advanced therapies market.